National Health Act 1953 - Amendment determination under paragraph 98C(1)(b) -conditions (No. PB 121 of 2010)

Overview

The National Health Act 1953 (the Act) forms the legislative basis for the Pharmaceutical Benefits Scheme (PBS), through which the Commonwealth provides access to a range of affordable medicines for Australians. The Act authorises the Minister to determine the conditions under which payments will be made by the Commonwealth for the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners. Pursuant to this authority, the Minister issued legislative instrument number PB 121 of 2010 to amend the conditions under paragraph 98C(1)(b) of the Act. These amendments, which came into effect on 1 January 2011, were based on recommendations from the Pharmaceutical Benefits Advisory Committee and aim to provide reliable, timely, and affordable access to medicines. The instrument amends the conditions set out in PB 119 of 2008 and is a legislative instrument for the purposes of the Legislative Instruments Act 2003.

Scope and Application

The National Health Act 1953, as amended, serves as the legislative foundation for the Pharmaceutical Benefits Scheme (PBS) which aims to provide Australians with reliable, timely, and affordable access to a wide range of medicines. Under this Act, the Commonwealth provides pharmaceutical benefits by making payments to approved pharmacists and approved medical practitioners subject to certain conditions. The Pharmaceutical Benefits Advisory Committee (PBAC) makes recommendations to the Minister, who then determines these conditions through legislative instruments. The instrument in question, PB 121 of 2010, amends a previous determination made in PB 119 of 2008, reflecting recommendations from the PBAC and coming into effect on 1 January 2011. The amendments outlined in Schedule 1 concern the specific conditions for payments related to the supply of pharmaceutical benefits, including changes to the forms and brands of pharmaceutical items that are eligible for such benefits. This legislative instrument is applicable nationally and applies to all approved pharmacists and medical practitioners supplying pharmaceutical benefits within the scope of the PBS.

Key Provisions

The National Health Act 1953 (the Act) governs the Pharmaceutical Benefits Scheme (PBS), through which the Commonwealth provides access to a range of medicines for all Australians. The Act, specifically under Part VII, provides the legislative basis for the PBS. Section 85(1) of the Act mandates that the Commonwealth will provide benefits in accordance with Part VII for pharmaceutical benefits. The Minister, under subsection 85(2), declares drugs and medicinal preparations applicable under Part VII by legislative instrument. These are known as listed drugs, as defined in subsection 84(1). The Minister also determines the form, manner of administration, and brand of these listed drugs by legislative instrument, as outlined in subsections 85(3), 85(5), and 85(6) respectively. These determinations collectively establish what constitutes a pharmaceutical benefit under Part VII of the Act. The obligations imposed by the Act on the parties and entities it governs include the necessity for the Minister to determine the conditions under which payments will be made by the Commonwealth in respect of the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners. This is pursuant to paragraph 98C(1)(b) of the Act. The Minister must consult with the Pharmaceutical Benefits Advisory Committee (PBAC), an independent body comprising members from various interests and professions, including consumers, health economists, community pharmacists, general practitioners, clinical pharmacologists, and medical specialists. The Minister must consider recommendations from the PBAC when determining the conditions for payments. These obligations ensure that the supply of pharmaceutical benefits aligns with the PBS objectives of providing reliable, timely, and affordable access to medicines. There are no specific offences, penalties, or civil/criminal consequences outlined for breaches of the conditions set by the Minister under the Act. However, failure to comply with the determined conditions may result in non-payment or the need to repay amounts already disbursed by the Commonwealth. The Act and related legislative instruments focus on the procedural and consultative requirements rather than prescribing specific penalties for non-compliance. The primary consequence of not adhering to the conditions would be financial, involving the non-receipt or repayment of benefits. This ensures that the PBS remains a reliable and effective system for providing pharmaceutical benefits.